Tests for latent tuberculosis infection and isoniazid preventive therapy

The Lancet Infectious Diseases

Volumn 12, Issue 11, 2012, Pages 827-828

  Dowdy, David W ^a,b   Golub, Jonathan E ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

HUMAN; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LETTER; PRIORITY JOURNAL; SOUTH AFRICA; TUBERCULIN TEST;

HUMANS; INTERFERON-GAMMA RELEASE TESTS; TUBERCULOSIS, PULMONARY;

EID: 84867919089     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70221-9     Document Type: Letter

References (5)

1. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:45-55.
2. Akolo C, Adetifa I, Shepperd S, Volmink J Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010, 1. CD000171.
3. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000, 2. CD001363.
4. Comstock GW, Ferebee SH, Hammes LM A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967, 95:935-943.
5. Comstock GW, Baum C, Snider DE Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979, 119:827-830.